Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.41 |
| ▸ | ABL1 | P00519 | 6/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.41 |
| ▸ | SRC | P12931 | 6/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | EED | O75530 | 2/20 | 0.34 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7126117 | 0.85 | RIPK2 (0.41) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL7118064 | 0.85 | PDE5A (0.35) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL7127426 | 0.80 | RIPK2 (0.44) | EGFRRIPK2TTK | |
| SCHEMBL7119176 | 0.79 | RIPK2 (0.39) | EGFRABL1RIPK2 | |
| SCHEMBL7125172 | 0.77 | EGFR (0.39) | EGFRFGFR1RIPK2KDR | |
| SCHEMBL7126590 | 0.76 | RIPK2 (0.43) | EGFRRIPK2TTK | |
| SCHEMBL7115986 | 0.74 | DYRK1A (0.38) | RIPK2KDRTTK | |
| SCHEMBL7118837 | 0.74 | DYRK1A (0.38) | EGFRRIPK2TTK | |
| SCHEMBL7128067 | 0.69 | ALDH1A1 (0.43) | RIPK2KDRTTKPDE5A | |
| SCHEMBL7125143 | 0.68 | IKBKB (0.49) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | EGFR 319/4885ABL1 212/4885FGFR1 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.